Skip to main content
SpringerLink
Log in

Designing antibodies for oncology

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par or superior to conventional drug therapies. This review outlines the various immunoglobulin design strategies currently available, techniques used to reduce Ig antigenicity and toxicity, and points to consider during the manufacture of antibodies for use in clinical oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mehren MM, Adams GP, Weiner LM: Monoclonal antibody therapy for cancer. Annu Rev Med 54: 343–369, 2003

    Article  CAS  Google Scholar 

  2. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M: Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther3: 107–121, 2003

    Article  CAS  PubMed  Google Scholar 

  3. Glennie MJ, van de Winkel JG: Renaissance of cancer therapeutic antibodies.Drug Discov Today 8: 503–510, 2003

    Article  CAS  PubMed  Google Scholar 

  4. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies fortherapy. Nature 332: 323–327, 1988

    Google Scholar 

  5. Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H: Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162:3663–3671, 1999

    CAS  PubMed  Google Scholar 

  6. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blattler WA, Rees AR, Guild BC: Humanization of murine monoclonalantibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91: 969–973, 1994

    CAS  PubMed  Google Scholar 

  7. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE: Willimmunogenicity limit the use, efficacy, and future development of therapeutic monoclonalantibodies? Clin Diagn Lab Immunol 1: 365–372, 1994

    Google Scholar 

  8. Pimm MV: Possible consequences of human antibody responses on thebiodistribution of fragments of human, humanized or chimeric monoclonal antibodies: A noteof caution. Life Sci 55: L45–L49, 1994

    Article  Google Scholar 

  9. Feldman M, Maini RN: Anti-TNF alphatherapy or rheumatoid arthritis: Whathave we learned? Ann Rev Immunol 19: 163–196, 2001

    Google Scholar 

  10. Moreland LW, Heck LW, Jr, Koopman WJ: Biologic agents for treatingrheumatoid arthritis. Concepts and progress. Arthritis Rheum 40: 397–409, 1997

    CAS  PubMed  Google Scholar 

  11. Kavanaugh AF: Anti-tumor necrosis factor-alpha monoclonal antibody therapyfor rheumatoid arthritis. Rheum Dis Clin North Am 24: 593–614, 1998

    Article  CAS  PubMed  Google Scholar 

  12. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J: Human anti-mouse antibody response to the injection of murine monoclonalantibodies against IL-6. Clin Exp Immunol 98: 323–329, 1994

    CAS  PubMed  Google Scholar 

  13. Garrison L, McDonnell ND: Etanercept: Therapeutic use in patients withrheumatoid arthritis. Ann Rheum Dis 58(Suppl 1): I65–I69, 1999

    Article  CAS  PubMed  Google Scholar 

  14. Maeda T, Yamada Y, Tawara M, Yamasaki R, Yakata Y, Tsutsumi C, Onimaru Y, Kamihira S, Tomonaga M: Successful treatment with a chimeric anti-CD20 monoclonal antibody(IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed ahuman anti-chimeric antibody. Int J Hematol 74: 70–75, 2001

    CAS  PubMed  Google Scholar 

  15. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA:Abciximab readministration: Results of the Reo Pro Readministration Registry. Circulation104: 870–875, 2001

    CAS  PubMed  Google Scholar 

  16. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended Rituximab (anti-CD20monoclonal antibody) therapy for relapsed or refractory low-grade or follicularnon-Hodgkin's lymphoma. Ann Oncol 10: 655–661, 1999

    Article  CAS  PubMed  Google Scholar 

  17. Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH: Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G inovarian carcinoma patients: A phase I study. Cancer 80: 2712–2720, 1997

    CAS  PubMed  Google Scholar 

  18. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE: Antitumor activity of a monoclonal antibody directed against gastrin-releasingpeptide in patients with small cell lung cancer. Chest 112: 256–261, 1997

    CAS  PubMed  Google Scholar 

  19. Soderlind E, Ohlin M, Carlsson R: Complementarity-determining region (CDR)implantation: A theme of recombination. Immunotechnology 4: 279–285, 1999

    CAS  PubMed  Google Scholar 

  20. Corti A, Barbanti E, Tempest PR, Carr FJ, Marcucci F: Idiotope determiningregions of a mouse monoclonal antibody and its humanized versions. Identification offramework residues that affect idiotype expression. J Mol Biol 235: 53–60, 1994

    CAS  PubMed  Google Scholar 

  21. Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, Harris WJ:Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virusinfection in vivo. Biotechnology (N Y) 9: 266–271, 1991

    CAS  Google Scholar 

  22. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H:Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748–752, 1992

    Article  CAS  PubMed  Google Scholar 

  23. Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H: Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162:3663–3671, 1999

    CAS  PubMed  Google Scholar 

  24. Hudson PJ, Souriau C: Engineered antibodies. Nat Med 9: 129–134, 2003

    Article  CAS  PubMed  Google Scholar 

  25. Kellermann SA, Green LL: Antibody discovery: The use of transgenic mice togenerate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13: 593–597, 2002

    Article  CAS  PubMed  Google Scholar 

  26. Kretzschmar T, von Ruden T: Antibody discovery: Phage display. Curr Opin Biotechnol 13: 598–602, 2002

    Article  CAS  PubMed  Google Scholar 

  27. Carter P, Merchant AM: Engineering antibodies for imaging and therapy. Curr Opin Biotechnol 8: 449–454, 1997

    Article  CAS  PubMed  Google Scholar 

  28. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol 9: 395–402, 1998

    Article  CAS  PubMed  Google Scholar 

  29. Adams GP, Weiner LM: Radioimmunotherapy of solid tumors: From fairytale toreality. Cancer Biother Radiopharm 16: 9–11, 2001

    Article  CAS  PubMed  Google Scholar 

  30. Eccles SA: Monoclonal antibodies targeting cancer: ‘Magic bullets’ or justthe trigger? Breast Cancer Res 3: 86–90, 2001

    Article  CAS  PubMed  Google Scholar 

  31. Johnson PW: The therapeutic use of antibodies for malignancy. Transfus Clin Biol 8: 255–259, 2001

    Article  CAS  PubMed  Google Scholar 

  32. Bindon CI, Hale G, Waldmann H: Importance of antigen specificity forcomplement-mediated lysis by monoclonal antibodies. Eur J Immunol 18: 1507–1514, 1988

    CAS  PubMed  Google Scholar 

  33. Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG: Engineering therapeuticantibodies for improved function. Biochem Soc Trans 30: 487–490, 2002

    CAS  PubMed  Google Scholar 

  34. Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG: Engineering therapeuticantibodies for improved function. Biochem Soc Trans 30: 487–490, 2002

    CAS  PubMed  Google Scholar 

  35. Presta LG: Engineering antibodies for therapy. Curr Pharm Biotechnol 3:237–256, 2002

    Article  CAS  PubMed  Google Scholar 

  36. Ravetch JV, Bolland S: Ig G Fc receptors. Annu Rev Immunol 19: 275–290, 2001

    Article  CAS  PubMed  Google Scholar 

  37. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D: Pharmacokinetics andbiodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13: 603–608, 2002

    Article  CAS  PubMed  Google Scholar 

  38. Dayan AD: Safety evaluation of biological and biotechnology-derivedmedicines. Toxicology 105: 59–68, 1995

    Article  CAS  PubMed  Google Scholar 

  39. Johnson PW: The therapeutic use of antibodies for malignancy. Transfus Clin Biol 8: 255–259, 2001

    Article  CAS  PubMed  Google Scholar 

  40. Lipsky MS, Sharp LK: From idea to market: The drug approval process. J Am Board Fam Pract 14: 362–367, 2001

    CAS  PubMed  Google Scholar 

  41. Waldmann TA, Levy R, Coller BS: Emerging Therapies: Spectrum of Applicationsof Monoclonal Antibody Therapy. Hematology (Am Soc Hematol Educ Program)394–408, 2000

  42. Waldmann H, Gilliland LK, Cobbold P, Hale G: Immunotherapy. In: Paul W (ed)Fundamental Immunology, 4th ed. Lippincott, Williams and Wilkins, 2000, Philadelphia, pp.1511–1529

    Google Scholar 

  43. Dyer MJ, Hale G, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies invivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431–1439, 1989

    CAS  PubMed  Google Scholar 

  44. Hale G, Clark M, Waldmann H: Therapeutic potential of rat monoclonalantibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity withhuman lymphocytes. J Immunol 134: 3056–3061, 1985

    CAS  PubMed  Google Scholar 

  45. Hale G, Swirsky D, Waldmann H, Chan LC: Reactivity of rat monoclonalantibody CAMPATH-1 with human leukaemia cells and its possible application for autologousbone marrow transplantation. Br J Haematol 60: 41–48, 1985

    CAS  PubMed  Google Scholar 

  46. Green SK, Karlsson MC, Ravetch JV, Kerbel RS: Disruption of cell-celladhesion enhances antibody-dependent cellular cytotoxicity: Implications forantibody-based therapeutics of cancer. Cancer Res 62: 6891–6900, 2002

    CAS  PubMed  Google Scholar 

  47. Kipps TJ, Parham P, Punt J, Herzenberg LA: Importance of immunoglobulinisotype in human antibody-dependent, cell-mediated cytotoxicity directed by murinemonoclonal antibodies. J Exp Med 161: 1–17, 1985

    Article  CAS  PubMed  Google Scholar 

  48. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J: In vitro mechanisms of action of rituximab on primarynon-Hodgkin lymphomas. Blood 101: 949–954, 2003

    Article  CAS  PubMed  Google Scholar 

  49. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101–110, 2002

    Article  CAS  PubMed  Google Scholar 

  50. Popkov M, Sidrac-Ghali S, Lusignan Y, Lemieux S, Mandeville R: Inhibition oftumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9. Eur J Cancer 37: 2484–2492, 2001

    Article  CAS  PubMed  Google Scholar 

  51. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW: Differential CD52expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumabactivity at the level of antigen presentation in allogeneic graft-host interactions intransplantation. Blood 101: 1422–1429, 2003

    Article  CAS  PubMed  Google Scholar 

  52. Kim KM, Shin EY, Moon JH, Heo TH, Lee JY, Chung Y, Lee YJ, Cho HM, Shin SU, Kang CY: Both the epitope specificity and isotype are important in the antitumor effect ofmonoclonal antibodies against Her-2/neu antigen. Int J Cancer 102: 428–434, 2002

    Article  CAS  PubMed  Google Scholar 

  53. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptorsmodulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446, 2000

    CAS  PubMed  Google Scholar 

  54. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptorsmodulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446, 2000

    CAS  PubMed  Google Scholar 

  55. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol26: 74–78, 1999

    CAS  PubMed  Google Scholar 

  56. Maloney DG: Mechanism of action of rituximab. Anticancer Drugs 12(Suppl 2):S1–S4, 2001

    CAS  PubMed  Google Scholar 

  57. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW: Differential CD52expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumabactivity at the level of antigen presentation in allogeneic graft-host interactions intransplantation. Blood 101: 1422–1429, 2003

    Article  CAS  PubMed  Google Scholar 

  58. Janeway CA, Traverse P, Walport M, Capra JD: Immunobiology: The immunesyustem in health and disease, 4th ed. Elsevier Science, London, 1999, pp 307–308

    Google Scholar 

  59. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M: Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther3: 107–121, 2003

    Article  CAS  PubMed  Google Scholar 

  60. Glennie MJ, Johnson PW: Clinical trials of antibody therapy. Immunol Today21: 403–410, 2000

    Article  CAS  PubMed  Google Scholar 

  61. Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solidtumors. Cancer Treat Rev 26: 269–286, 2000

    Article  CAS  PubMed  Google Scholar 

  62. Prodinger WM, Wurzner R, Erdei A, Dierich MP: Complement. In Paul W (ed)Fundamental Immunology, 4th ed. Lippincott, Williams and Wilkins, Philadelphia, 1999, pp967–995

    Google Scholar 

  63. Dyer MJ, Hale G, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies invivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431–1439, 1989

    CAS  PubMed  Google Scholar 

  64. Maloney DG: Mechanism of action of rituximab. Anticancer Drugs 12(Suppl 2):S1–S4, 2001

    CAS  PubMed  Google Scholar 

  65. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA:Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60–70, 1999

    CAS  PubMed  Google Scholar 

  66. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES:Targeting multiple Her-2 epitopes with monoclonal antibodies results in improvedantigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8: 1720–1730, 2002

    CAS  PubMed  Google Scholar 

  67. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N: Targetedanti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in thetreatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25: 705–708, 1997

    CAS  PubMed  Google Scholar 

  68. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M: Biologic response of B lymphoma cells to anti-CD20monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated celllysis. Blood 95: 3900–3908, 2000

    CAS  PubMed  Google Scholar 

  69. Harjunpaa A, Junnikkala S, Meri S: Rituximab (anti-CD20) therapy of B-celllymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand JImmunol 51: 634–641, 2000

    CAS  Google Scholar 

  70. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptorsmodulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446, 2000

    CAS  PubMed  Google Scholar 

  71. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N: Targetedanti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in thetreatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25: 705–708, 1997

    CAS  PubMed  Google Scholar 

  72. Maloney DG: Mechanism of action of rituximab. Anticancer Drugs 12(Suppl 2):S1–S4, 2001

    CAS  PubMed  Google Scholar 

  73. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-releasesyndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte countsafter treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–2224, 1999

    CAS  PubMed  Google Scholar 

  74. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP: Humanized monoclonalantibody CAMPATH-1H: Myeloma cell expression of genomic constructs, nucleotide sequence ofcDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovarycell-derived material. Clin Exp Immunol 87: 105–110, 1992

    CAS  PubMed  Google Scholar 

  75. Dyer MJ, Hale G, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies invivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431–1439, 1989

    CAS  PubMed  Google Scholar 

  76. Dyer MJ: The role of CAMPATH-1 antibodies in the treatment of lymphoidmalignancies. Semin Oncol 26: 52–57, 1999

    CAS  PubMed  Google Scholar 

  77. Hale G, Swirsky DM, Hayhoe FG, Waldmann H: Effects of monoclonalanti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1: 321–334, 1983

    CAS  PubMed  Google Scholar 

  78. Hale G, Clark M, Waldmann H: Therapeutic potential of rat monoclonalantibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity withhuman lymphocytes. J Immunol 134: 3056–3061, 1985

    CAS  PubMed  Google Scholar 

  79. Woynarowska BA, Woynarowski JM: Preferential targeting of apoptosis in tumorversus normal cells. Biochim Biophys Acta 1587: 309–317, 2002

    CAS  PubMed  Google Scholar 

  80. Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 11:S22–S26, 2001

    CAS  PubMed  Google Scholar 

  81. Pettit SJ, Seymour K, O'Flaherty E, Kirby JA: Immune selection in neoplasia:Towards a microevolutionary model of cancer development. Br J Cancer 82: 1900–1906, 2000

    CAS  PubMed  Google Scholar 

  82. White CA, Weaver RL, Grillo-Lopez AJ: Antibody-targeted immunotherapy fortreatment of malignancy. Annu Rev Med 52: 125–145, 2001

    Article  CAS  PubMed  Google Scholar 

  83. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M: Anticancer antibodies. Am JClin Pathol 119: 472–485, 2003

    CAS  Google Scholar 

  84. Adams GP, Weiner LM: Radioimmunotherapy of solid tumors: From fairytale toreality. Cancer Biother Radiopharm 16: 9–11, 2001

    Article  CAS  PubMed  Google Scholar 

  85. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH: Pretargetedradioimmunotherapy of cancer: Progress step by step. J Nucl Med 44: 400–411, 2003

    PubMed  Google Scholar 

  86. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: Gemtuzumab ozogamicin in relapsed acutemyeloid leukemia. Clin Cancer Res 7: 1490–1496, 2001

    CAS  PubMed  Google Scholar 

  87. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP: Campath-1H (anti-CD52) monoclonal antibody therapy inlymphoproliferative disorders. Med Oncol 18: 99–107, 2001

    CAS  PubMed  Google Scholar 

  88. Sievers EL: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1: 893–901, 2001

    Article  CAS  PubMed  Google Scholar 

  89. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G: Pretargeted adjuvant radioimmunotherapy withyttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 86: 207–212, 2002

    Article  CAS  PubMed  Google Scholar 

  90. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM: Phase II trialof yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients withmetastatic colon cancer. Clin Cancer Res 6: 406–414, 2000

    CAS  PubMed  Google Scholar 

  91. Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA:Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and(90)Y-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N″, N″-tetraacetic acid(DOTA)-biotin. Cancer Res 62: 5755–5760, 2002

    CAS  PubMed  Google Scholar 

  92. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D: A comparative evaluation of conventional andpretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98:2535–2543, 2001

    Article  CAS  PubMed  Google Scholar 

  93. Goshorn S, Sanderson J, Axworthy D, Lin Y, Hylarides M, Schultz J:Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein forpretargeted cancer therapy. Cancer Biother Radiopharm 16: 109–123, 2001

    Article  CAS  PubMed  Google Scholar 

  94. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR: Cure of human carcinoma xenografts by a singledose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97:1802–1807, 2000

    Article  CAS  PubMed  Google Scholar 

  95. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M: Pre-targeted locoregionalradioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminarytherapeutic results. Cancer Biother Radiopharm 16: 227–235, 2001

    Article  CAS  PubMed  Google Scholar 

  96. Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM: Clinical optimization of pretargeted radioimmunotherapy withantibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med 41: 131–140, 2000

    CAS  PubMed  Google Scholar 

  97. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM: Phase II trialof yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients withmetastatic colon cancer. Clin Cancer Res 6: 406–414, 2000

    CAS  PubMed  Google Scholar 

  98. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M: Pre-targeted locoregionalradioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminarytherapeutic results. Cancer Biother Radiopharm 16: 227–235, 2001

    Article  CAS  PubMed  Google Scholar 

  99. Weiden PL, Breitz HB: Pretargeted radioimmunotherapy (PRIT) for treatment ofnon-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol 40: 37–51, 2001

    CAS  PubMed  Google Scholar 

  100. Gura T: Therapeutic antibodies: Magic bullets hit the target. Nature 417:584–586, 2002

    Article  CAS  PubMed  Google Scholar 

  101. Gura T: Therapeutic antibodies: Magic bullets hit the target. Nature 417:584–586, 2002

    Article  CAS  PubMed  Google Scholar 

  102. Chadd HE, Chamow SM: Therapeutic antibody expression technology. Curr Opin Biotechnol 12: 188–194, 2001

    Article  CAS  PubMed  Google Scholar 

  103. Reavy B, Ziegler A, Diplexcito J, Macintosh SM, Torrance L, Mayo M:Expression of functional recombinant antibody molecules in insect cell expression systems.Protein Expr Purif 18: 221–228, 2000

    CAS  PubMed  Google Scholar 

  104. Sanchez L, Ayala M, Freyre F, Pedroso I, Bell H, Falcon V, Gavilondo JV:High cytoplasmic expression in E. coli, purification, and in vitro refolding of a singlechain Fv antibody fragment against the hepatitis B surface antigen. J Biotechnol 72:13–20, 1999

    CAS  PubMed  Google Scholar 

  105. Allison DE, Gourlay SG, Koren E, Miller RM, Fox JA: Pharmacokinetics ofrhu MAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normalhealthy human volunteers. Bio Drugs 16: 63–70, 2002

    CAS  Google Scholar 

  106. Looareesuwan S, Sjostrom L, Krudsood S, Wilairatana P, Porter RS, Hills F, Warrell DA: Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatmentfor severe malaria. Am J Trop Med Hyg 61: 26–33, 1999

    CAS  PubMed  Google Scholar 

  107. Juweid M, Sharkey RM, Behr TM, Swayne LC, Dunn R, Ying Z, Siegel JA, Hansen HJ, Goldenberg DM: Clinical evaluation of tumor targeting with the anticarcinoembryonicantigen murine monoclonal antibody fragment, MN-14 F(ab)2. Cancer 78: 157-168, 1996

    Article  CAS  PubMed  Google Scholar 

  108. Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine GM, Izon D, Gascon P: Phase I clinical evaluation of a new murine monoclonalantibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinalcarcinomas. Cancer 73: 864–877, 1994

    CAS  PubMed  Google Scholar 

  109. Wada K, Watanabe T, Tadokoro M, Sakamoto J, Murayama H, Sakuma S, Takagi H:[Radioimmunodetection of colorectal cancer, using anti-CEA monoclonal antibody CEA 102:Whole Ig G versus F(ab')2 fragments]. Nippon Geka Gakkai Zasshi 93: 266–273, 1992

    CAS  PubMed  Google Scholar 

  110. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J: In vivo tumor targeting of a recombinant single-chainantigen-binding protein. J Natl Cancer Inst 82: 1191–1197, 1990

    CAS  PubMed  Google Scholar 

  111. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol 9:395–402, 1998

    Article  CAS  PubMed  Google Scholar 

  112. Swartz JR: Advances in Escherichia coli production of therapeutic proteins.Curr Opin Biotechnol 12: 195–201, 2001

    Article  CAS  PubMed  Google Scholar 

  113. De Bernardez CE: Protein refolding for industrial processes. Curr Opin Biotechnol 12: 202–207, 2001

    Google Scholar 

  114. Swartz JR: Advances in Escherichia coli production of therapeutic proteins.Curr Opin Biotechnol 12: 195–201, 2001

    Article  CAS  PubMed  Google Scholar 

  115. Andersen DC, Krummen L: Recombinant protein expression for therapeuticapplications. Curr Opin Biotechnol 13: 117–123, 2002

    Article  CAS  PubMed  Google Scholar 

  116. Houdebine LM: Antibody manufacture in transgenic animals and comparisonswith other systems. Curr Opin Biotechnol 13: 625–629, 2002

    Article  CAS  PubMed  Google Scholar 

  117. Chu L, Robinson DK: Industrial choices for protein production bylarge-scale cell culture. Curr Opin Biotechnol 12: 180–187, 2001

    Article  CAS  PubMed  Google Scholar 

  118. Chu L, Robinson DK: Industrial choices for protein production bylarge-scale cell culture. Curr Opin Biotechnol 12: 180–187, 2001

    Article  CAS  PubMed  Google Scholar 

  119. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol 9:395–402, 1998

    Article  CAS  PubMed  Google Scholar 

  120. BD Kelley, Biochemical engineering: Bioprocessing of therapeutic proteins.Curr Opin Biotechnol 12: 173–174, 2001

    Article  CAS  PubMed  Google Scholar 

  121. Laken HA, Leonard MW: Understanding and modulating apoptosis in industrialcell culture. Curr Opin Biotechnol 12: 175–179, 2001

    Article  CAS  PubMed  Google Scholar 

  122. Grunfeld H, Moore P: Reduction of bovine immunoglobulin contamination frommonoclonal antibodies by SOURCE 15PHE chromatography. J Immunol Methods 201: 233–241, 1997

    Article  CAS  PubMed  Google Scholar 

  123. Jiskoot W, Van Hertrooij JJ, Hoven AM, Klein Gebbinck JW, Van der Velden-de Groot, Crommelin DJ, Beuvery EC: Preparation of clinical grade monoclonal antibodies fromserum-containing cell culture supernatants. J Immunol Methods 138: 273–283, 1991

    CAS  PubMed  Google Scholar 

  124. Laken HA, Leonard MW: Understanding and modulating apoptosis in industrialcell culture. Curr Opin Biotechnol 12: 175–179, 2001

    Article  CAS  PubMed  Google Scholar 

  125. Siegel R, Naveh D: Large scale downstream processing of monoclonalantibodies. Bioseparation 1: 351–359, 1991

    Google Scholar 

  126. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748–752, 1992

    Article  CAS  PubMed  Google Scholar 

  127. Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H: Elimination of the immunogenicity of therapeutic antibodies. J Immunol 162:3663–3671, 1999

    CAS  PubMed  Google Scholar 

  128. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D: Pharmacokinetics andbiodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13: 603–608, 2002

    Article  CAS  PubMed  Google Scholar 

  129. Dayan AD: Safety evaluation of biological and biotechnology-derivedmedicines. Toxicology 105: 59–68, 1995

    Article  CAS  PubMed  Google Scholar 

  130. Lipsky MS, Sharp LK: From idea to market: the drug approval process. J Am Board Fam Pract 14: 362–367, 2001

    CAS  PubMed  Google Scholar 

  131. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M: Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther3: 107–121, 2003

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. TanTec Biosystems Inc., 11 Des Arbres, Dollard-Des-Ormeaux, Montreal, Quebec, Canada, H9G 3C2

    Jerome E. Tanner

Authors
  1. Jerome E. Tanner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerome E. Tanner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanner, J.E. Designing antibodies for oncology. Cancer Metastasis Rev 24, 585–598 (2005). https://doi.org/10.1007/s10555-005-6197-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-005-6197-x

Keywords

Search

Navigation